Stocks analysis

ABBV vs AIG Stock Comparison

Scores Breakdown

Metric ABBV AIG
📈 Growth 15/30 23/30
💰 Profitability 16/20 12/20
🏦 Financial Health 12/20 15/20
💵 Valuation 12/20 10/20
⚠️ Risk (lower is better) 6/10 6/10
Overall Score 59/100 64/100

Side-by-Side Summaries

ABBV Analysis AIG Analysis

📈 Growth & Financial Trajectory

8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1.

💰 Margins & Cash Flow

Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings.

🛡️ Balance Sheet & Liquidity

Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B.

⚠️ Key Drivers & Risks

  • Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress.
  • Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues stayed broadly flat in the $6.4B–$7.2B range, peaking at about $7.18B in 2024 Q4 and easing to around $6.65B by 2026 Q1. Net income progressed from a sizable quarterly loss in 2024 Q3 (~-$3.88B) to positive earnings from 2024 Q4 onward, with a peak near $1.14B in 2025 Q2, then moderating to roughly $0.52B–$0.76B across 2025 Q3–2026 Q1. This reflects meaningful earnings leverage despite a relatively flat revenue base, with a notable mid-2025 uplift followed by stabilization.

💰 Margins & Cash Flow

Operating margins swung from the mid-teens to the low- to mid-20s in 2025 Q2 (peak around 22%), indicating strong operating leverage when volumes align with cost structure. Across quarters, the average margin sits in the low-teens, roughly around 12%. Operating cash flow was positive in most periods, signaling solid cash generation from core activities, while investing cash flow fluctuated and financing cash flow was typically negative, reflecting ongoing debt management and capital activity.

🛡️ Balance Sheet & Liquidity

Assets run roughly $160–$166B with liabilities near $120–$125B and equity around $40–$41B, suggesting a solid asset base and meaningful equity cushion. The structure implies resilience supported by recurring operating cash flow, albeit with ongoing financing activity.

⚠️ Key Drivers & Risks

  • Drivers: Steady core insurance volumes and favorable investment environment supporting earnings uplift.
  • Risks: Earnings volatility from reserve development and sensitivity to macro/regulatory shifts that can affect margins.